{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117689","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.723227+00:00","generated_at":"2026-06-21T19:28:03.203925+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BrainStorm Q3 net loss $6.9M; FDA refuses to file NurOwn BLA for ALS","bullets":["Cash & short-term deposits $7.4M as of Sep 30, down from $12.2M on Jun 30.","Net loss $6.9M in Q3 2022 vs $5.3M in Q3 2021; EPS -$0.19 vs -$0.15.","FDA refused to file new BLA for NurOwn in ALS; company plans to request Type A meeting.","Phase 3 ALS post-hoc analyses at NEALS meeting addressed ALSFRS-R floor effect.","Phase 2 progressive MS trial results published showing safety and preliminary efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117689","json":"https://secwatch.observer/filing/0001104659-22-117689.json","markdown":"https://secwatch.observer/filing/0001104659-22-117689.md","text":"https://secwatch.observer/filing/0001104659-22-117689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922117689/0001104659-22-117689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922117689/tm2230408d1_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:28:03.203925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"861332461b9ca083fcc33dbeac20d66e47cdb3be","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022, was approximately $6.9 million, EPS Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19.","evidence_excerpt":"Net loss for the three months ended September 30, 2022, was approximately $6.9 million, as compared to a net loss of approximately $5.3 million for the three months ended September 30, 2021. Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19 and $0.15, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465922117689/0001104659-22-117689-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the three months ended September 30, 2022, was approximately $6.9 million"},{"label":"EPS","value":"Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}